Skip to main navigation

Skip to Content

Overview
Stock Information
News & Events
Financials
- SEC Filings
- Quarterly Results
Governance
- Governance Highlights
- Committee Composition
Investor Resources

News Releases

2018 Investor Presentation

Year

Sep 22, 2023

HARMONY BIOSCIENCES STATEMENT ON U.S. FOOD & DRUG ADMINISTRATION (FDA) INTERIM RESPONSE TO CITIZEN PETITION

Sep 20, 2023

HARMONY BIOSCIENCES PRESIDENT & CEO JEFFREY M. DAYNO, M.D., NAMED TO 2023 PHARMAVOICE 100 LIST OF TOP INDUSTRY LEADERS

Sep 13, 2023

HARMONY BIOSCIENCES TO PARTICIPATE IN 2023 CANTOR GLOBAL HEALTHCARE CONFERENCE

Sep 07, 2023

HARMONY BIOSCIENCES ANNOUNCES US FOOD & DRUG ADMINISTRATION ORPHAN DRUG DESIGNATION FOR PITOLISANT FOR TREATMENT OF IDIOPATHIC HYPERSOMNIA

Aug 28, 2023

HARMONY BIOSCIENCES REITERATES CONFIDENCE IN WAKIX® (PITOLISANT) PATENTS FOLLOWING FAVORABLE DECISION BY U.S. PATENT AND TRADEMARK OFFICE (USPTO) TO DENY PETITION FOR REEXAMINATION

Aug 14, 2023

HARMONY BIOSCIENCES TO ACQUIRE ZYNERBA PHARMACEUTICALS, INC.

Aug 01, 2023

Harmony Biosciences Reports Second Quarter 2023 Financial Results and Business Updates

Aug 01, 2023

HARMONY BIOSCIENCES ANNOUNCES $125 MILLION SHARE REPURCHASE PROGRAM

Jul 27, 2023

HARMONY BIOSCIENCES ENTERS INTO $185 MILLION TERM LOAN FACILITY

Jul 25, 2023

Harmony Biosciences Announces Funding for Unique Community Initiatives Through its Patients and Progress at the Heart Awards Programs

Pagination

Current page 1
Page 2
Page 3
Next page
Last page

Displaying 1 - 10 of 26

Site - Shareholder Tools

Copyright © 2023 Harmony Biosciences All rights reserved.

Facebook
Twitter
LinkedIn
Google+